These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17329869)

  • 21. Oxybutynin topical and transdermal formulations: an update.
    Staskin DR; Salvatore S
    Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formulation study of oxybutynin patches.
    Minghetti P; Cilurzo F; Pagani S; Casiraghi A; Assandri R; Montanari L
    Pharm Dev Technol; 2007; 12(3):239-46. PubMed ID: 17613887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of Temperature Profiles in Skin and Transdermal Delivery System When Exposed to Temperature Gradients In Vivo and In Vitro.
    Zhang Q; Murawsky M; LaCount T; Hao J; Kasting GB; Newman B; Ghosh P; Raney SG; Li SK
    Pharm Res; 2017 Jul; 34(7):1491-1504. PubMed ID: 28493100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous pharmacodynamics of transdermally delivered isosorbide dinitrate.
    Hori M; Ohtsuka S; Sunami M; Guy RH; Maibach HI
    Pharm Res; 1990 Dec; 7(12):1298-301. PubMed ID: 2095569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray.
    Laufen H; Leitold M
    Arzneimittelforschung; 1992 Jul; 42(7):931-5. PubMed ID: 1418058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: Rufus Cartwright and Linda Cardozo. Transdermal oxybutynin: sticking to the facts. Eur urol 2007;51:907-14.
    Cornel EB
    Eur Urol; 2007 Jul; 52(1):286-7; author reply 287. PubMed ID: 17434252
    [No Abstract]   [Full Text] [Related]  

  • 29. New insights in oxybutynin chemical stability: Identification in transdermal patches of a new impurity arising from oxybutynin N-oxide rearrangement.
    Canavesi R; Aprile S; Giovenzana GB; Di Sotto A; Di Giacomo S; Del Grosso E; Grosa G
    Eur J Pharm Sci; 2016 Mar; 84():123-31. PubMed ID: 26796144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
    Ho C
    Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of isosorbide dinitrate concentration on its skin permeability from adhesive matrix devices.
    Hatanaka T; Oguchi M; Sugibayashi K; Morimoto Y
    Chem Pharm Bull (Tokyo); 1991 Jul; 39(7):1802-5. PubMed ID: 1777935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
    Sand PK; Goldberg RP; Dmochowski RR; McIlwain M; Dahl NV
    Am J Obstet Gynecol; 2006 Dec; 195(6):1730-5. PubMed ID: 17132474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The MATRIX study: assessment of health-related quality of life in adults with the use of transdermal oxybutynin.
    Newman DK
    Director; 2008; 16(1):22-5. PubMed ID: 19343871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The MATRIX study: evaluating the data in older adults.
    Newman DK
    Director; 2008; 16(3):15-9. PubMed ID: 19343887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a membrane-controlled transdermal therapeutic system containing isosorbide dinitrate.
    Ocak F; Ağabeyoğlu I
    Int J Pharm; 1999 Apr; 180(2):177-83. PubMed ID: 10370188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in medical management of overactive bladder.
    Richelson E; Elliott DS
    Mayo Clin Proc; 2003 Jun; 78(6):681-3. PubMed ID: 12934775
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.
    Saltzstein L
    Urol Nurs; 2005 Aug; 25(4):260-2. PubMed ID: 16225342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
    Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
    J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration.
    Gleason JM; Daniels C; Williams K; Varghese A; Koyle MA; Bägli DJ; Pippi Salle JL; Lorenzo AJ
    J Pediatr Urol; 2014 Aug; 10(4):753-7. PubMed ID: 24477421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.